New study suggests combination of statin and omega-3 fatty acid may provide cardioprotective effects

New findings from an in vitro study, led by researchers at Brigham and Women's Hospital (BWH), show that the combination of statins and eicosapentaenoic acid (EPA), an omega-3 fatty acid, may potentially reduce cardiovascular risk. This research is being presented May 1 at a peer-reviewed poster session at the National Lipid Association Scientific Sessions in Orlando, Florida.

"We know that endothelial cell dysfunction is emerging as an early and important predictor of and plays an essential role in plaque development. Treatments that provide beneficial effects on could have very important implications for a patient population at high risk for ," said R. Preston Mason, PhD, of BWH's Department of Medicine and lead author of the study. "We found that a combination of statins and EPA omega-3 fatty acid, or fish oil, had on and function."

Using human tissue, researchers analyzed whether EPA could enhance the benefits of statins on endothelial cells. Blood vessels from human umbilical vein cells were collected from healthy donors and then subjected to disease-like conditions in the laboratory using oxidized low-density lipoproteins (LDL). Using nanotechnology approaches, researchers measured the release of molecules from the endothelial cells including nitric oxide, an essential regulator of blood vessel health. The researchers found that the combination of EPA and a statin was more than 50 percent better than the statin alone in reversing endothelial damage.

Researchers conclude that there is a potent and favorable interaction between the omega-3 fatty acid, EPA, and widely used statins, and suggest that a therapeutic strategy with this combination may be beneficial patients with increased risk for CV disease.

These new results may also underscore the importance of coupling high-quality statin therapies with an omega-3 agent such as EPA in potentially reducing , in addition to treating elevated triglycerides. High circulating triglyceride levels are considered a risk factor associated with cardiovascular disease, along with HDL, LDL cholesterol and blood pressure. New strategies to help patients manage this aspect of cardiovascular risk show promise in the overall prevention and treatment of heart disease.

The researchers note that future research is needed, particularly in humans, including cardiovascular outcomes data in randomized clinical trials.

add to favorites email to friend print save as pdf

Related Stories

Are statins good for your love life?

Mar 29, 2014

Statins are associated with a significant improvement in erectile function, a fact researchers hope will encourage men who need statins to reduce their risk of heart attack to take them, according to research to be presented ...

Recommended for you

Barriers preventing post-stroke care

Jul 24, 2014

For stroke victims, rehabilitation is crucial to their recovery. But a Flinders University study conducted in Singapore found that rehabilitation rates following discharge from hospital are poor because of gaps in the continuum ...

Home-based rehabilitation for CVD patients

Jul 24, 2014

Patients who are found to suffer from cardiovascular diseases often have long years of treatment ahead of them and are urged to drastically change their lifestyle. But what is probably the most difficult ...

New remote patient monitoring devices available

Jul 24, 2014

(HealthDay)—Several new remote patient monitoring devices with useful applications are available or under development, according to an article published July 8 in Medical Economics.

Monitoring pulse after stroke may prevent a second stroke

Jul 23, 2014

New research suggests that regularly monitoring your pulse after a stroke or the pulse of a loved one who has experienced a stroke may be a simple and effective first step in detecting irregular heartbeat, a major cause of ...

User comments